Evidence map›Paper›PMID 26207639›Full record

Observational studyPloS one2015

Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis.

Jianjun Sun, Li Liu, Jiayin Shen, Tangkai Qi, Zhenyan Wang, Wei Song, Renfang Zhang, Hongzhou Lu

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jianjun SunKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Li LiuKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jiayin ShenKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Tangkai QiKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Zhenyan WangKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Wei SongKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Renfang ZhangKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Hongzhou LuKey Laboratory of Medical Molecular Virology of MOE/MOH, Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Department of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, China; Department of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, China.
Shanghai Public Health Clinical Center · CNHuashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the reasons and risk factors for modification of the first combined antiretroviral therapy (cART) currently used for HIV infected patients who were treatment naïve in Shanghai China.

methodsMaking a retrospective observational research on treatment naïve patients with HIV infection who initiated cART during the period of September 1st 2005---December 1st 2013. The demographic and clinical data were collected from the first visit to the time of the first regimen modification or the last visit in December 1st, 2014. The reasons of treatment modification were recorded. Survival analysis of modification was made by Kaplan-Meier curves analysis and log rank test, and a Cox multiple regression model was constructed to identify related factors of modification.

resultsA total number of the eligible participants were 3372 and 871(25.8%) patients changed their first cART regimen. The median follow up was 22 months [interquartile range (IQR) 14-39]. Among patients who modified the original regimen, drug toxicity occurred in 805(92.4%) participants and 44(5.1%) experienced treatment failure. In multiple regression analysis regimen modification was associated with patients' age more than 40 years old (aHR 1.224, 95%CI 1.051-1.426, P = 0.010), CD4 less than 200(aHR 1.218, 95%CI 1.044-1.421, P = 0.012) and the initial regimen they received. Compared with the regimen of TDF+3TC+EFV, patients with regimen of d4T+3TC+NVP, d4T+3TC+EFV, AZT+3TC+NVP or AZT+3TC+EFV were 10.4, 8.2, 6.4, 2.5 times more likely to modify their initial regimen, respectively.

conclusionsThe main reason for the regimen switch was drug toxicity and main risk factors for regimen modification were age older than 40 years, CD4 cell counts less than 200 at baseline and regimen they received. Among the 2NRTI plus 1NNRTI regimens, the co-formulation of d4T+3TC+NVP had the highest risk for modification while the regimen of TDF+3TC+EFV was the most tolerable treatment regimen in first years' follow up.

Indexed as

AdultAnti-HIV AgentsAnti-Retroviral AgentsChinaDrug MonitoringDrug SubstitutionDrug Therapy, CombinationFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedRetrospective StudiesRisk FactorsYoung AdultAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID26207639
PMCPMC4514877
OpenAlexW1893469951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.